References
- McLeod S. Infectious keratitis. In: Yanoff M, Duker J, eds. Ophthalmology. St. Louis: Mosby; 2004
- Thomas P, Geraldine P. Infectious keratitis. Curr Opin Infect Dis 2007;20:129–141
- Armstrong RA. The microbiology of the eye. Ophthal Physiol Opt 2000;20:429–441
- Egger SF, Ruckhofer J, Alzner E, et al. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthal Res 2001;33:117–120
- Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49:S79–S83
- Sweetman S. Matindale: the complete drug reference. London: Pharmaceutical Press; 2009
- Patton TF, Robinson JR. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. J Pharm Sci 1976;65:1295–1301
- Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine. J Pharm Sci 1977;66:1222–1228
- Middleton DL, Leung SS, Robinson JR. Bioadhesive drug delivery systems. Boca Raton (FL): CRC Press; 1990
- Wilhelmus KR, Abshire RL. Corneal ciprofloxacin precipitation during bacterial keratitis. Am J Ophthalmol 2003;136:1032–1037
- Budai M, Szabó Z, Zimmer A, et al. Studies on molecular interactions between nalidixic acid and liposomes. Int J Pharm 2004;279:67–79
- Lang JC, Roehrs RE, Rodeheaver DP, et al. Design and evaluation of ophthalmic pharmaceutical products. In: Banker GS, Rhodes CT, eds. Modern phatmaceutics. New York: Marcel Dekker; 2002
- Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Del Rev 2005;57:1595–1639
- Burgalassi S, Chetoni P, Panichi L, et al. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocul Pharmacol Ther 2000;16:497–509
- Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990;74:477–480
- Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Rel 2007;122:119–134
- Felt O, Baeyens V, Zignani M, et al. Mucosal drug delivery-ocular. Encyclopedia of controlled drug delivery. Geneva: University of Geneva; 1999
- Zagon IS, Klocek MA, Sassani JW, et al. Corneal safety of topically applied naltrexone. J Ocul Pharmacol Ther 2006;22:377–387
- GraphPad InStat version 3.00, GraphPad Software, Inc., San Diego, CA, USA, 1995. Available from: www.graphpad.com
- Dillen K, Vandervoort J, van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles. Int J Pharm 2006;314:72–82
- Sinko PJ. Pharmaceutical polymers. In: Troy DB, ed. Martin’s physical pharmacy and pharmaceutical sciences. Philadelphia (PA): Lippincott Williams & Wilkins; 2011
- Burgess DL. Drug dissolution: method development. Auckland: The Australian & New Zealand Chapters of the Controlled Release Society: In Vitro Drug Release and Dissolution Testing Workshop; 2010
- Harbell JW, Raabe HA, Evans MG, Curren RD. Histopathology associated with opacity and permeability changes in bovine corneas in vitro. The Toxicologist 1999;48:336–337
- Harbell JW, Mun G, Curren RD. Application of histological evaluation to enhance the bovine opacity and permeability (BCOP) assay. The 45th Annual Society of Toxicology Meeting, San Diego, CA, USA; 2006
- Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 2002;54:37–51